This included 3 patients treated with neoadjuvant anti–PD-L1 (atezolizumab) before cystectomy on a clinical trial (ClinicalTrials.gov NCT02451423), who had matched PBMC samples both before and after immunotherapy, along with their postimmunotherapy tumor data (Supplemental Dataset 1). This evidence concerns the gene CD274 and neoplasm.